Chandan Healthcare shares list with 3.84% premium at ₹165.10 on the NSE SME

Chandan Healthcare share price lists with 3.84% premium at ₹165.10 on the NSE SME on Friday. The Chandan Healthcare IPO had received strong response being subscribed more than 7 times. However Grey Market premium indicated decent listing but with marginal premium

Chandan Healthcare share price movement

The Chandan Healthcare shares listed at ₹165.10, a decent 3.8% premium over the upper price band of the issue price of ₹159. The Chandan Healthcare share price thereafter gained further to highs of ₹173.35, which meant another 3% gains after opening.

Chandan Healthcare subscription status indicated strong interest

Chandan Healthcare initial Public offer that opened for subscription on 10 February 2025 and closed on 12th February 2025 was subscribed 7.04 times. By February 12, 2025,, the public offering had been subscribed to 2.44 times in the retail category, 7.58 times in the QIB category, and 18.85 times in the NII category.

Chandan Healthcare IPO GMP or Grey Market premium that stood at +3 after the issue closed however had dipped to Nil by listing day as per details from investorgain.com. The same means that the shares of Chandan Healthcare that were available in the Grey Market at ₹3 more than the offer price after the close of the IPO, however lost all premium by listing day . This also implied that market participants while were expecting Chandan Healthcare shares to list at ₹162, a premium of 1.89% or ₹3 more than the upper band of the offer price at ₹159, however by listing day only expected shares to be listed at the upper price band and without any listing gains

Chandan Healthcare IPO other details

The Chandan Healthcare IPO was a ₹107.36 crore book-built offering. The issuance is a mix of an offer to sell 23.00 lakh shares for a total of ₹36.57 crores and a new issue of 44.52 lakh shares worth ₹70.79 crores.

Chandan Healthcare Limited was founded in September 2003 and operates diagnostic facilities in North India that provide radiology and pathology testing services.

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.